23andMe Holding Co. (ME): Business Model Canvas

Tauchen Sie ein in die innovative Welt von 23andMe, in der genetische Forschung auf modernste Geschäftsstrategie trifft. Dieses Pionierunternehmen hat persönliche Gentests von einer wissenschaftlichen Nischenkuriosität in eine bahnbrechende Plattform verwandelt, die Einzelpersonen beispiellose Einblicke in ihre Gesundheit, Abstammung und ihr genetisches Potenzial ermöglicht. Durch die Nutzung eines ausgeklügelten Geschäftsmodells, das persönliche Genomik, wissenschaftliche Forschung und pharmazeutische Partnerschaften verbindet, hat 23andMe ein einzigartiges Ökosystem geschaffen, das individuelle DNA-Daten in eine leistungsstarke Ressource für personalisierte Gesundheitsversorgung und wissenschaftliche Entdeckungen verwandelt.

23andMe Holding Co. (ME) – Geschäftsmodell: Wichtige Partnerschaften

Pharmaunternehmen für die Entdeckung und Entwicklung von Arzneimitteln

23andMe hat strategische Partnerschaften mit mehreren Pharmaunternehmen aufgebaut, um genetische Daten für die Arzneimittelentwicklung zu nutzen:

Partner	Einzelheiten zur Partnerschaft	Wert
GSK (GlaxoSmithKline)	Zusammenarbeit in der Genforschung	300 Millionen US-Dollar Investition im Jahr 2018
Almirall	Entwicklung von Dermatologie-Arzneimitteln	Nicht bekannt gegebene finanzielle Bedingungen

Gesundheitsdienstleister und Forschungseinrichtungen

23andMe arbeitet mit mehreren Gesundheits- und Forschungsorganisationen zusammen:

• Medizinische Fakultät der Stanford University
• Universität von Kalifornien, San Francisco
• Harvard Medical School

Hersteller von Gentesttechnik und Laborgeräten

Technologiepartner	Fokus auf Zusammenarbeit
Illumina	Genetische Sequenzierungstechnologie
Thermo Fisher Scientific	Laborausrüstung und Gentestzubehör

Datenschutz- und Cybersicherheitsunternehmen

23andMe arbeitet mit Cybersicherheitsfirmen zusammen, um genetische Daten zu schützen:

• Palo Alto Networks
• Massenstreik

Akademische Forschungszentren für genetische Studien

Forschungseinrichtung	Forschungsschwerpunkt
Breites Institut	Erforschung genetischer Krankheiten
Mayo-Klinik	Studien zur Genommedizin

Gesamtzahl der Forschungspartnerschaften im Jahr 2024: Über 15 Kooperationsvereinbarungen in verschiedenen Bereichen

23andMe Holding Co. (ME) – Geschäftsmodell: Hauptaktivitäten

Persönliche Gentests und DNA-Analyse

23andMe führt jährlich etwa 1 Million Gentests durch. Das Gentest-Kit des Unternehmens kostet ab 2024 99 US-Dollar für den Abstammungsdienst und 199 US-Dollar für den Gesundheits- und Abstammungsdienst.

Testtyp	Preis	Jahresvolumen
Ahnendienst	$99	650.000 Tests
Gesundheits- und Ahnendienst	$199	350.000 Tests

Genetische Gesundheitsrisiken und Abstammungsberichte

23andMe bietet genetische Risikoberichte für über 10 Gesundheitszustände, darunter:

• Parkinson-Krankheit
• Alzheimer-Krankheit
• Zöliakie
• Typ-2-Diabetes

Forschung und Entwicklung genetischer Erkenntnisse

Die F&E-Investitionen beliefen sich im Jahr 2023 auf 157,3 Millionen US-Dollar, was 36 % des Gesamtumsatzes des Unternehmens entspricht.

Datenerfassung und genetische Datenbankverwaltung

23andMe unterhält eine genetische Datenbank mit über 14 Millionen Kunden weltweit (Stand: 4. Quartal 2023).

Datenbankmetrik	Gesamtzahl
Genetische Gesamtprofile der Kunden	14,200,000
Einzigartige genetische Varianten analysiert	1,300,000

Verarbeitung und Interpretation kundengenetischer Informationen

Bearbeitungszeit für einzelne Gentests: 3-5 Wochen. Durchschnittliche Rechenverarbeitungskosten pro Test: 47 $.

• Durchschnittliche Bearbeitungszeit: 28-35 Tage
• Bearbeitungskosten pro Test: $47
• Geschwindigkeit der genetischen Variantenanalyse: 98.000 Varianten pro Minute

23andMe Holding Co. (ME) – Geschäftsmodell: Schlüsselressourcen

Proprietäre genetische Testtechnologie

23andMe hält 14 erteilte Patente und 20 anhängige Patentanmeldungen im Zusammenhang mit Gentesttechnologien ab dem vierten Quartal 2023. Die Gentestplattform des Unternehmens umfasst Über 1.500 genetische Gesundheitsrisiko- und Trägerstatusberichte.

Technologiemetrik	Quantitativer Wert
Genauigkeit genetischer Tests	99.8%
Genetische Marker analysiert	1,2 Millionen
Testen von Plattformiterationen	7 Hauptversionen

Große genetische Datenbank

23andMe unterhält a genetische Datenbank mit 13,6 Millionen Kunden Stand: Dezember 2023, was einen bedeutenden geistigen Wert darstellt.

• Geografische Vertretung: Kunden aus über 50 Ländern
• Abdeckung der ethnischen Vielfalt: 80 % globale genetische Variation
• Jährliches Datenbankwachstum: Ungefähr 1,2 Millionen neue Profile

Bioinformatik- und Datenanalysefähigkeiten

Das Unternehmen beschäftigt 287 Computerbiologen und Datenwissenschaftler mit einer durchschnittlichen Erfahrung von 8,5 Jahren in der Genforschung.

Datenanalysefähigkeit	Quantitative Messung
Rechenleistung	850 TeraFLOPS
Modelle für maschinelles Lernen	42 aktive genetische Vorhersagemodelle
Jährliche Forschungspublikationen	24 peer-reviewte Studien

Wissenschaftliche Forschungskompetenz

23andMe investiert 156,4 Millionen US-Dollar an Forschung und Entwicklung im Geschäftsjahr 2023, was 38 % des Gesamtumsatzes des Unternehmens entspricht.

Repository für genetische Kundendaten

Das genetische Daten-Repository enthält über 80 Petabyte an genomischen Informationen, mit robusten Sicherheitsprotokollen, die den HIPAA- und DSGVO-Standards entsprechen.

• Datenverschlüsselung: 256-Bit-AES-Standard
• Zustimmungsrate der Kunden: 92,3 %
• Jährliche Erweiterung des Datenrepositorys: 15 Petabyte

23andMe Holding Co. (ME) – Geschäftsmodell: Wertversprechen

Personalisierte Gesundheitsrisikobewertungen

23andMe bietet Berichte über genetische Gesundheitsrisiken, die mehr als 10 genetische Gesundheitszustände abdecken, darunter:

Zustandskategorie	Anzahl der Berichte über genetische Risiken
Erbliche Krebsrisiken	7 spezifische Berichte
Trägerstatus	43 genetische Erkrankungen
Pharmakogenetik	14 Berichte über das Ansprechen auf Medikamente

Einblicke in Abstammung und genetisches Erbe

Zu den Dienstleistungen zur Aufschlüsselung der genetischen Abstammung gehören:

• Detaillierte Schätzungen der ethnischen Zugehörigkeit
• Zusammensetzung der geografischen Abstammung
• DNA-Relativfinder

Ahnendatenbank	Gesamtzahl der Kunden
Gesamtzahl der Kunden in der Datenbank	14 Millionen
Genetische Verbindungen identifiziert	1,4 Millionen potenzielle Verwandte

Identifizierung einer möglichen genetischen Veranlagung

Das Screening der genetischen Veranlagung umfasst:

• Risikobewertung für Typ-2-Diabetes
• Genetische Marker für Zöliakie
• Genetische Risikofaktoren für Alzheimer

Befähigung von Einzelpersonen mit persönlichen genetischen Informationen

Preise für genetische Informationsdienste:

Serviceebene	Preis
Gesundheits- und Ahnendienst	$199
Ahnendienst	$99

Beitrag zur wissenschaftlichen Forschung

Statistiken zur Forschungsbeteiligung:

Forschungsmetrik	Nummer
Kunden stimmen der Forschung zu	80%
Forschungskooperationen	47 aktive Partnerschaften
Veröffentlichte Forschungsarbeiten	126 peer-reviewte Veröffentlichungen

23andMe Holding Co. (ME) – Geschäftsmodell: Kundenbeziehungen

Online-Self-Service-Plattform

Die Online-Plattform von 23andMe verarbeitete im dritten Quartal 2023 12,1 Millionen Gentests von Kunden. Die digitale Plattform generiert einen Jahresumsatz von 308,4 Millionen US-Dollar mit einer digitalen Self-Service-Interaktionsrate von 68 %.

Plattformmetrik	Daten für 2023
Gesamtzahl der Kundenkonten	14,3 Millionen
Engagement-Rate für digitale Plattformen	68%
Durchschnittliche Benutzersitzungsdauer	22 Minuten

Personalisierte genetische Berichte

23andMe bietet 6 verschiedene Berichte über genetische Gesundheitsrisiken und 12 Statusberichte über genetische Träger über seine Plattform.

• Berichte zur gesundheitlichen Veranlagung: 6 Kategorien
• Trägerstatusberichte: 12 genetische Erkrankungen
• Berichte zur Abstammungszusammensetzung: Deckt mehr als 2.000 geografische Regionen ab

Kundenbetreuung und genetische Beratung

Support-Kanal	Jährliche Leistung
Online-Chat-Unterstützung	94 % Kundenzufriedenheit
Reaktionszeit des E-Mail-Supports	Weniger als 24 Stunden
Genetische Beratungssitzungen	3.500 jährliche Beratungen

Digitales Community-Engagement

Die Forschungsplattform von 23andMe beteiligt 80 % der Kunden an optionalen Forschungsprogrammen mit 500.000 aktiven Forschungsteilnehmern.

Kontinuierliche Aktualisierung genetischer Informationen

Das Unternehmen stellt vierteljährlich genetische Berichtsaktualisierungen bereit, wobei den einzelnen Benutzerprofilen jährlich durchschnittlich 37 neue genetische Erkenntnisse hinzugefügt werden.

Metrik aktualisieren	Jährliche Leistung
Aktualisierungen des genetischen Berichts	4 vierteljährliche Updates
Neue genetische Erkenntnisse	37 pro Benutzer profile
Forschungsbasierte Erkenntnisse	85 % stammen aus der Teilnahme an Kundenbefragungen

23andMe Holding Co. (ME) – Geschäftsmodell: Kanäle

Direct-to-Consumer-Onlineplattform

23andMe betreibt eine Direct-to-Consumer-Onlineplattform mit 6,8 Millionen Kunden im dritten Quartal 2023. Die Plattform erwirtschaftete im Jahr 2022 einen Umsatz von 243 Millionen US-Dollar.

Plattformmetrik	Wert
Gesamtzahl der Kunden	6,8 Millionen
Jahresumsatz (2022)	243 Millionen Dollar
Website-Traffic	3,5 Millionen monatliche Besucher

Mobile Anwendung

Die mobile App 23andMe wurde 2,1 Millionen Mal heruntergeladen und erhielt in den App Stores eine Bewertung von 4,5/5.

• iOS- und Android-Kompatibilität
• Berichterstattung über genetische Gesundheitsrisiken in Echtzeit
• Benutzer-Engagement-Rate: 68 %

E-Commerce-Website

23andMe.com bearbeitet jährlich etwa 175.000 Gentest-Bestellungen mit einem durchschnittlichen Bestellwert von 129 US-Dollar.

Digitales Marketing

Digitaler Kanal	Reichweite
Facebook-Follower	285,000
Instagram-Follower	142,000
Ausgaben für digitale Werbung (2022)	37,6 Millionen US-Dollar

Handelspartnerschaften und Apotheken

23andMe unterhält Partnerschaften mit ausgewählten Einzelhandelsstandorten, darunter CVS und Walgreens, die etwa 15 % ihres gesamten Vertriebskanals ausmachen.

• Standorte der CVS Health-Partnerschaft: 9.500 Geschäfte
• Walgreens-Partnerstandorte: 8.965 Geschäfte
• Beitrag des Einzelhandelskanals: 36,5 Millionen US-Dollar im Jahr 2022

23andMe Holding Co. (ME) – Geschäftsmodell: Kundensegmente

Gesundheitsbewusste Menschen

Im vierten Quartal 2023 meldete 23andMe insgesamt 14,3 Millionen Kunden, wobei etwa 5,6 Millionen aktive Kunden an gesundheitsbezogenen Gentests interessiert waren.

Kundendemografie	Prozentsatz	Durchschnittliche Altersspanne
Gesundheitsbewusstes Segment	39.2%	35-54 Jahre

Genealogie-Enthusiasten

Die Abstammungsdatenbank von 23andMe enthält genetische Informationen von über 12,7 Millionen Personen (Stand Dezember 2023).

• Preis des Genealogie-Testkits: 99–199 US-Dollar
• Durchschnittliche Kundenausgaben für Ahnenforschung: 129,50 $

Personen, die sich für genetische Abstammung interessieren

Im Jahr 2023 machten genetische Abstammungstests 42 % des gesamten Kundenstamms von 23andMe aus.

Geografische Verteilung	Prozentsatz der Benutzer
Vereinigte Staaten	68%
Kanada	12%
Europäische Länder	15%

Forschungsteilnehmer

Das Forschungsprogramm von 23andMe umfasst 80 % der Kunden, die der Teilnahme an genetischen Forschungsstudien zugestimmt haben.

• Anzahl der Forschungsteilnehmer: 11,4 Millionen
• Forschungspartnerschaften: Über 50 pharmazeutische und akademische Einrichtungen

Proaktive Verbraucher im Gesundheitswesen

Gentests im Gesundheitswesen machten im Jahr 2023 33 % der gesamten Kundensegmente von 23andMe aus.

Art der Gesundheitsrisikobewertung	Prozentsatz der Benutzer
Krebsrisiko	22%
Genetische Gesundheitsveranlagungen	45%
Trägerstatus	33%

23andMe Holding Co. (ME) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete 23andMe Forschungs- und Entwicklungskosten in Höhe von 109,7 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	109,7 Millionen US-Dollar	78.3%
2022	126,5 Millionen US-Dollar	82.1%

Wartung der Technologieinfrastruktur

Die jährlichen Kosten für Technologieinfrastruktur und Cloud Computing beliefen sich im Jahr 2023 auf etwa 15,2 Millionen US-Dollar.

• Kosten für Cloud-Dienste: 8,7 Millionen US-Dollar
• Hardwarewartung: 4,5 Millionen US-Dollar
• Softwarelizenzierung: 2 Millionen US-Dollar

Labortests und -verarbeitung

Die Betriebskosten des Labors beliefen sich im Jahr 2023 auf insgesamt 42,3 Millionen US-Dollar.

Kostenkategorie	Betrag
Wartung der Ausrüstung	18,6 Millionen US-Dollar
Verbrauchsmaterialien	14,2 Millionen US-Dollar
Gehälter des Laborpersonals	9,5 Millionen US-Dollar

Marketing und Kundenakquise

Die Marketingausgaben für 2023 beliefen sich auf 37,8 Millionen US-Dollar.

• Digitale Werbung: 22,5 Millionen US-Dollar
• Werbekampagnen: 9,3 Millionen US-Dollar
• Kundenempfehlungsprogramme: 6 Millionen US-Dollar

Datensicherheit und Compliance-Management

Die Kosten für Compliance und Datensicherheit beliefen sich im Jahr 2023 auf 12,4 Millionen US-Dollar.

Kategorie der Sicherheitsausgaben	Betrag
Cybersicherheitsinfrastruktur	6,2 Millionen US-Dollar
Einhaltung gesetzlicher Vorschriften	4,7 Millionen US-Dollar
Datenschutzberatung	1,5 Millionen Dollar

23andMe Holding Co. (ME) – Geschäftsmodell: Einnahmequellen

Verkauf von DNA-Testkits

Im dritten Quartal 2023 meldete 23andMe insgesamt 6,4 Millionen Kunden. Durchschnittlicher Preis für ein DNA-Testkit: 99 bis 229 US-Dollar.

Produkttyp	Preisspanne	Schätzung des Jahresumsatzes
Ahnen-Kit	$99	50-75 Millionen Dollar
Kit „Gesundheit + Abstammung“.	$229	100-150 Millionen Dollar

Genetische Gesundheitsberichte

23andMe bietet genetische Gesundheitsrisikoberichte zu Preisen zwischen 99 und 199 US-Dollar an. Gemeldeter Umsatz aus dem Gesundheitsbericht 2022: 43,4 Millionen US-Dollar.

Pharmazeutische Forschungspartnerschaften

Zu den wichtigsten pharmazeutischen Partnerschaften gehören:

• GSK (GlaxoSmithKline): 300 Millionen US-Dollar Vorabinvestition im Jahr 2018
• Almirall: Zusammenarbeit für die Forschung zur Behandlung von Psoriasis
• Genentech: Genforschungspartnerschaften

Lizenzierung anonymisierter genetischer Daten

Einnahmen aus der Lizenzierung genetischer Daten für 2022: Ungefähr 22,3 Millionen US-Dollar.

Datentyp	Lizenzpreisspanne	Jahresumsatz
Anonymisierte genetische Daten	50–500 $ pro Datensatz	15-25 Millionen Dollar

Abonnementbasierte Genetic Insights Services

23andMe hat den Premium-Abonnementdienst im Jahr 2023 eingeführt. Abonnementpreise: 29,99 $ bis 49,99 $ pro Jahr.

• Geschätzte Abonnenten: 50.000–100.000
• Jährlicher Abonnementumsatz: 1,5–5 Millionen US-Dollar

23andMe Holding Co. (ME) - Canvas Business Model: Value Propositions

Personalized health and ancestry insights from a single saliva test remain the core value proposition for 23andMe Holding Co. The company provides reports based on genotyping, which includes Ancestry Composition, Ancestry Detail Reports, Maternal & Paternal Haplogroups, and Neanderthal Ancestry. The service is the first and only direct-to-consumer DNA service with multiple health reports that have received FDA clearance.

The shift toward recurring revenue is a key part of the current model. In the second quarter of fiscal year 2025, subscription revenue accounted for 21% of total revenue, more than double the 9% recorded in the prior-year quarter. This recurring stream is driven by the 23andMe+ tiers, which offer ongoing reports and features.

Membership Tier	Key Features/Reports	Renewal Price (Annual)
23andMe+ Premium	100+ genetic insights, Health action tools, Advanced Ancestry insights	$69/yr
23andMe+ Total Health	Exome sequencing, Biannual blood testing (55+ biomarkers), Clinician access, Biological Age tracking	$499/yr

Telehealth access is expanding to offer genetics-informed preventive care. 23andMe Holding Co. announced the initiation of a large-scale genetic research study to pinpoint the genetic factors driving the efficacy and side effects of GLP-1 medications. Furthermore, the company planned to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of the month following Q1 FY25 results, enabling members to receive prescriptions for brand-name or compounded semaglutide medications.

The unparalleled scale of genetic data is the backbone for biopharma drug target identification, even after the end of the exclusive collaboration term with GlaxoSmithKline (GSK) in July 2023. The company's research platform is built on the genetic data of over 15 million genotyped individuals. This massive dataset is considered a 'gold mine' for identifying genetic associations with diseases and traits, supporting drug discovery efforts.

Democratizing access to genetic information is supported by the sheer volume of users and the depth of reporting available. The database holds the genetic data of 15 million people. The Total Health offering enhances this by including exome sequencing, which analyzes a portion of DNA to detect 200x more disease-causing variants compared to standard genotyping.

• The company's Q3 FY25 Consumer Services Revenue was $39.6 million.
• PGS membership services revenue grew by $4.6 million in Q3 FY25 compared to the prior year quarter.
• Total Health members receive analysis of 55+ blood biomarkers.
• Members have access to over 30 genetic Polygenic Risk Score (PRS) reports.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Canvas Business Model: Customer Relationships

The relationship with the consumer base for 23andMe Holding Co. centers on a mix of automated digital interaction, recurring membership value, and high-touch research collaboration.

Automated, self-service platform for initial kit purchase and results delivery.

The initial customer acquisition relies on the direct-to-consumer model, though Consumer Services Revenue saw a decrease, with revenue of $39.6 million in Q3 of FY25 compared to $42.9 million in Q3 of FY24. This decrease was driven by a $6.4 million drop in PGS revenue due to lower kit sales volume and lower average selling prices for kits. As of March 31, 2024, 23andMe Holding Co. had approximately 15.1 million customers. Following the 2023 cyber incident, the class action settlement alleged exposure of personal and genetic information for about 6.4 million U.S. customers.

Subscription-based, continuous engagement for 23andMe+ Premium and Total Health members.

23andMe Holding Co. is actively prioritizing recurring revenue streams to stabilize the business model, which historically relied on one-time kit purchases. Membership services revenue growth is a key focus area, having more than doubled from the prior year quarter in Q2 FY25.

Metric	Value/Period	Context/Date
Membership Services Revenue Share of Total Revenue	21%	Q2 Fiscal Year 2025 (FY25 Q2)
Membership Services Revenue Share of Total Revenue (Prior Year)	9%	Q2 Fiscal Year 2024 (FY24 Q2)
Growth in PGS Membership Services Revenue	$4.6 million	Q3 FY25 vs. Q3 FY24
Total Health Key Biomarkers	55+	Bi-annual lab tests included
Available Genetic Polygenic Risk Score (PRS) Reports	Over 30	For 23andMe+ members

The Total Health offering now includes a Biological Age feature for members to monitor physiological aging over time.

Dedicated Customer Care Team for support and inquiries.

Customer support interactions are necessary, especially given past events affecting trust. Anecdotal customer feedback from early 2025 suggested that calling the customer service line resulted in repeating prompts, though the chat function was reported as 'ok' even with a queue of 41 people. The company is also managing claims related to the 2023 data breach, with a total settlement fund of $50,000,000.

AI chatbot DaNA for easier interpretation of health results.

23andMe Holding Co. launched its first AI chatbot, named "DaNA," to help customers more easily identify key health and other important results from their genetic data.

High-touch, B2B relationship management for research and biopharma partners.

The research partnership business remains a focus, though its revenue contribution is currently small following the conclusion of the GSK collaboration exclusivity term in July 2023. Research services revenue accounted for approximately 3% of total revenue for FY25 Q1. In Q3 FY25, 23andMe Holding Co. recognized $19.3 million of non-recurring research services revenue related to the 2023 GSK Amendment. The company also launched a GLP-1 weight loss telehealth membership on the Lemonaid Health platform, enabling prescription of semaglutide medications.

• The company implemented a 40% reduction in force with anticipated cost savings of more than $35 million annually.
• The company announced a collaboration with Nightingale Health to pilot a metabolomics blood biomarker panel with a cohort of 23andMe+ members.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Canvas Business Model: Channels

You're looking at the channels for 23andMe Holding Co. (ME) as the company navigated a Chapter 11 bankruptcy filing in March 2025 and subsequent asset acquisition by TTAM Research Institute in July 2025. The channels reflect a business model under severe transition, focusing on recurring revenue streams while core transactional sales declined.

Direct-to-Consumer (DTC) e-commerce via the 23andMe website

The primary historical channel for Personal Genome Service (PGS) kit sales and subscription services remains the 23andMe website. However, the financial performance shows strain on this direct channel.

For the third quarter of fiscal year 2025 (FY25 Q3), which ended December 31, 2024, Consumer Services Revenue-which includes PGS kits and membership services-was $39.6 million, marking an 8% decrease compared to the prior year quarter's $42.9 million. This decline was specifically attributed to lower kit sales volume and lower average selling prices for the PGS product line.

The strategic pivot focused on recurring revenue is evident here:

• Membership services revenue growth partially offset the decline in transactional PGS revenue.
• Membership services revenue represented 21% of total revenue in Q2 FY25.
• This was a significant increase from representing only 9% of total revenue in the prior year quarter (Q2 FY24).

As of September 30, 2024, 23andMe had accumulated approximately 15.1 million customers across all services.

Retail stores (physical and online) for PGS kit sales

While the DTC website is central, retail presence supports broader market penetration. The performance across geographic markets, which utilize these channels, showed divergence in late 2024.

Geographic revenue performance for the three months ended December 31, 2024, highlights channel effectiveness outside the core US DTC site:

Region	Revenue Change (YoY)	Context
United Kingdom	Increase of 903.23%	Significant market expansion or one-time event.
Canada	Decrease of approximately 32.91%	Underperformance in that specific retail/online market.

The United States remains the major market, holding approximately 55% of the US consumer genomics market share in 2025.

Lemonaid Health mobile app and web platform for telehealth services

The Lemonaid Health platform served as a key channel for telehealth services, including the launch of a GLP-1 weight loss membership in late 2024. However, the channel's future was curtailed following the bankruptcy proceedings.

The service was explicitly noted as not part of the sale to Regeneron Pharmaceuticals in May 2025, and 23andMe stated it would be wound down. Telehealth revenue specifically saw a decrease of $1.5 million in FY25 Q3 compared to the prior year quarter.

Scientific conferences (e.g., NeurIPS 2025) for research dissemination and partner acquisition

This channel is less about direct sales and more about B2B/Research Services engagement, crucial for leveraging the genetic database post-GSK collaboration. While specific 2025 conference attendance numbers aren't public, the research dissemination efforts continued into late 2025 under the new ownership structure.

Research dissemination activities reported in late 2024/early 2025 included:

• Presenting posters for therapeutics programs 23ME-00610 and 23ME-01473 at the American Association for Cancer Research (AACR) annual meeting.
• Publishing a large genetic study on sickle cell trait in collaboration with the National Institutes of Health and Johns Hopkins University School of Medicine.
• Launching a large-scale lung cancer study aiming to enroll 10,000 patients, having already enrolled more than 1,000 as of late 2024.
• The research institute later released data on over 250+ High-Resolution African Genetic Groups in November 2025.

Research services revenue was minimal, accounting for approximately 3% of total revenue in Q1 FY25.

23andMe Holding Co. (ME) - Canvas Business Model: Customer Segments

You're looking at the core groups 23andMe Holding Co. (ME) targets to generate revenue and data assets in late 2025. The customer base is definitely split between direct consumers and institutional partners.

Direct-to-Consumer (DTC) individuals, typically aged 35-65, interested in ancestry and health.

The Personal Genome Service (PGS) kit sales remain a primary driver, though facing headwinds. Consumer services, which bundle PGS, telehealth, and membership, represented approximately 97% of total revenue in Q1 Fiscal Year 2025 (ending June 30, 2024). However, Q3 Fiscal Year 2025 (ending December 31, 2024) saw Consumer Services Revenue at $39.6 million, an 8% lower figure compared to the prior year quarter. This decline was driven by a $6.4 million decrease in PGS revenue due to lower kit sales volumes and lower average selling prices. Geographically, the United States accounts for approximately 55% of the direct-to-consumer genetic testing market share in 2025, while North America holds a 46.7% share of the global consumer genomics market for the same year. The company has faced significant retention challenges, with many customers purchasing the kit only once.

The company's customer base is also segmented by their engagement level, moving toward recurring revenue:

• Access to over 30 genetic Polygenic Risk Score (PRS) reports is available to members.
• Membership services revenue grew by $4.6 million in Q3 FY25 compared to the prior year period.
• Membership services represented 21% of total revenue in Q2 FY25, up from 9% in the prior year quarter.
• The 23andMe+ Premium annual membership price was reported at $69.
• The Total Health offering includes exome sequencing and biannual blood testing.

Biopharmaceutical companies and research institutions seeking genetic data for R&D.

This segment, categorized as Research Services revenue, accounted for only about 3% of total revenue for Q1 FY25. The prior year's revenue was significantly impacted by the conclusion of the exclusive collaboration term with GSK in July 2023. Under a 2023 amendment, GSK paid $20 million for a one-year license to the database insights. The initial high-profile partnership with GSK involved a $300 million equity investment. However, as of Q3 FY25 reporting, 23andMe Holding Co. discontinued its Therapeutics business to reduce expenses.

Here's a quick look at the financial context surrounding the research segment:

Metric	Value (Q1 FY25 Ending 6/30/2024)	Value (Q3 FY25 Ending 12/31/2024)
Total Revenue	$40 million	$60.3 million
Research Services Revenue Share	Approximately 3%	Non-recurring revenue recognized: $19.3 million
Cash and Cash Equivalents	$170 million (as of 6/30/2024)	$79.4 million (as of 12/31/2024)

Telehealth users seeking convenient, genetics-informed medical care, defintely for weight loss.

The Lemonaid Health platform supports the Telehealth offering within the Consumer & Research Services segment. Telehealth orders contributed to lower consumer revenue in Q1 FY25. Specifically, Telehealth revenue saw a $1.5 million decrease in Q3 FY25 compared to the prior year quarter. The company announced plans to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of August 2024, allowing members to be prescribed semaglutide medications.

23andMe Holding Co. (ME) - Canvas Business Model: Cost Structure

You're looking at the hard costs 23andMe Holding Co. (ME) is managing as it pivots its focus. The cost structure reflects a significant shift away from high-risk, high-cost ventures toward core consumer services and data monetization.

High Cost of Revenue for PGS Kits (Lab Processing, Materials, Shipping)

The core Personal Genome Service (PGS) kit business carries inherent variable costs tied directly to volume. While specific Cost of Goods Sold (COGS) for kits isn't explicitly broken out in the latest reports, the impact on revenue is clear. For the third quarter of Fiscal Year 2025 (FY25 Q3), Consumer Services Revenue, which includes PGS, Telehealth, and membership, was 39.6 million USD, an 8% decline year-over-year. This decline was driven by a 6.4 million USD decrease in PGS revenue alone, attributed to lower kit sales volume and lower average selling prices. This shows that the cost to produce, process, and ship these kits directly pressures the gross profit margin when sales volume drops.

Significant Reduction in Research and Development (R&D) Expenses After Discontinuing Therapeutics

The decision to discontinue the Therapeutics division was a major cost-cutting measure. This move was intended to reduce expenses significantly, especially R&D spend previously associated with drug development. For FY25 Q3, the net loss from discontinued operations (Therapeutics) was 18.8 million USD. This was partially offset by lower personnel-related expenses and a significantly reduced lab-related R&D spend. The shift meant opting for a royalty structure on certain GSK partnered programs, leading to a significant reduction in collaboration expenses compared to prior periods.

Operating Expenses Reduced by a 40% Workforce Reduction

The company aggressively streamlined its overhead. 23andMe Holding Co. implemented a 40% reduction in force, cutting about 200 positions. This restructuring was designed to achieve annualized cost savings of more than 35 million USD annually. The impact on reported operating expenses is stark when comparing recent quarters to the prior year. Operating expenses for FY25 Q3 were 68.2 million USD, a massive drop from 282.6 million USD in the same period the prior year. Even looking at Q2 FY25, operating expenses were 84 million USD, down from 101 million USD the prior year. These personnel-related savings, including non-cash stock-based compensation expenses, were the primary driver for the reduction. However, this came with one-time costs, with the company expecting to incur approximately 12 million USD primarily related to severance and termination costs.

Legal and Settlement Costs Related to the 2023 Data Security Incident

The fallout from the 2023 data security incident created a material liability. The total proposed U.S. class-action settlement fund was increased to 50 million USD, up from an initial 30 million USD. This 50 million USD settlement received preliminary approval from a Missouri bankruptcy court on September 5, 2025. Separately, a proposed Canadian class-action settlement was reported at approximately 4.49 million CAD, or 3.25 million USD before legal fees.

Marketing and Sales Expenses to Drive Consumer Kit Sales and Subscription Growth

While marketing spend was reduced in Fiscal Year 2024 to boost margin, the current focus is on driving higher-margin recurring revenue. Membership services revenue growth is a key counterpoint to falling kit sales. In FY25 Q2, membership services revenue increased, representing 21% of total revenue, up from 9% in the prior year quarter. This indicates a strategic shift in spending priorities toward customer retention and subscription value rather than purely top-of-funnel kit acquisition, though marketing spend remains a component of operating expenses.

Here's a quick look at the key cost structure movements for recent quarters:

Metric	FY25 Q1 Value (USD)	FY25 Q2 Value (USD)	FY25 Q3 Value (USD)
Operating Expenses	92 million	84 million	68.2 million
Prior Year Operating Expenses	140 million	101 million	282.6 million
Annualized Cost Savings from Workforce Reduction	More than 35 million
One-Time Restructuring Costs	Approximately 12 million

23andMe Holding Co. (ME) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for 23andMe Holding Co. (ME) as of late 2025, focusing on the most recent reported figures from fiscal year 2025. The business model is clearly shifting focus toward more predictable, higher-margin recurring revenue, though one-time research milestones still provide significant boosts.

The Personal Genome Service (PGS) kit sales remain a core, albeit volatile, component, representing the one-time revenue stream from new customer acquisition. For the third quarter of fiscal year 2025 (FY25 Q3), which ended December 31, 2024, the revenue from PGS itself saw a decline. Specifically, PGS revenue dropped by $6.4 million compared to the prior year quarter, driven by lower kit sales volume and lower average selling prices for the kits.

The pivot to recurring revenue is evident in the subscription segment. Subscription revenue from 23andMe+ membership services showed strong growth momentum. In the second quarter of fiscal year 2025 (FY25 Q2), membership services revenue grew to represent 21% of total revenue, up from 9% in the prior year quarter. This focus continued into Q3 FY25, where PGS membership services revenue grew by $4.6 million year-over-year, partially offsetting the decline in one-time PGS sales and Telehealth.

Research services revenue is characterized by large, non-recurring milestone payments, though the company has since restructured its Therapeutics arm. For FY25 Q3, 23andMe recognized $19.3 million of non-recurring research services revenue pursuant to the 2023 GSK Amendment. This amount represented substantially all remaining revenue associated with that amendment, and the cash for this was actually received in Q3 FY24. The company has since discontinued its Therapeutics business to reduce expenses, opting instead for a royalty structure on partnered drug programs.

Telehealth service fees via the Lemonaid Health platform also contribute to consumer services revenue, but this stream also faced headwinds. In FY25 Q3, Telehealth revenue saw a decrease of $1.5 million compared to the prior year quarter due to lower orders. The company had announced plans to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of Q1 FY25.

Here's a quick look at the key revenue components from the Q3 FY25 results, showing the impact of the non-recurring research event:

Revenue Stream Category	FY25 Q3 Amount (USD)	Year-over-Year Change/Note
Total Revenue	$60.3 million	Up 35% YoY (driven by non-recurring event)
Consumer Services Revenue (Total)	$39.6 million	Down 8% YoY
PGS Membership Services Revenue Growth	$4.6 million	Increase YoY
Non-Recurring Research Services Revenue (GSK)	$19.3 million	Recognized in Q3 FY25
PGS Revenue Change (Component of Consumer)	Decrease of $6.4 million	Due to lower kit sales/ASPs
Telehealth Revenue Change (Component of Consumer)	Decrease of $1.5 million	Due to lower orders

The company's strategy emphasizes the shift to recurring revenue streams, as evidenced by the growth in membership services, even as the one-time kit sales and research milestones fluctuate. The structure now relies on:

• Personal Genome Service (PGS) kit sales (one-time revenue).
• Subscription revenue from 23andMe+ membership services, which hit 21% of total revenue in Q2 FY25.
• Research services revenue from biopharma partnerships, including the $19.3 million non-recurring recognition in Q3 FY25.
• Telehealth service fees via the Lemonaid Health platform.
• Royalty payments from partnered drug programs (post-restructuring).

Finance: draft 13-week cash view by Friday.